Breast cancer Femara 2.5 mg oral tablet<unk>  is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women. Comparison with tamoxifen Tamoxifen is also used to treat hormonally-responsive breast cancer, but it does so by interfering with the estrogen receptor. However,<unk>  is effective only in post-menopausal women, in whom estrogen is produced predominantly in peripheral tissues (i.e. in adipose tissue, like that of the breast) and a number of sites in the brain. In pre-menopausal women, the main source of estrogen is from the ovaries not the peripheral tissues, and<unk>  is ineffective. In the BIG 1–98 Study, of post-menopausal women with hormonally-responsive breast cancer,<unk>  reduced the recurrence of cancer, but did not change survival rate, compared to tamoxifen. Ovulation induction<unk>  has been used for ovulation induction by fertility doctors since 2001 because it has fewer side-effects than clomiphene (Clomid) and less chance of multiple gestation. A study of 150 babies following treatment with either<unk>  alone or<unk>  and gonadotropins presented at the American Society of Reproductive Medicine 2005 Conference found no difference in overall abnormalities but did find a significantly higher rate of locomotor and cardiac abnormalities among the group having taken<unk>  compared to natural conception. A larger, follow-up study with 911 babies compared those born following treatment with<unk>  to those born following treatment with clomiphene. That study also found no significant difference in the rate of overall abnormalities, but found that congenital cardiac anomalies was significantly higher in the clomiphene group compared to the<unk>  group. Despite this, India banned the usage of<unk>  in 2011, citing potential risks to infants. In 2012, an Indian parliamentary committee said that the drug controller office colluded with<unk> 's makers to approve the drug for infertility in India and also stated that<unk> 's use for infertility was illegal worldwide; however, such off-label uses are legal in many countries such as the US and UK. Other uses The antiestrogen action of<unk>  has been shown to be useful in pretreatment for termination of pregnancy, in combination with misoprostol. It can be used in place of mifepristone, which is expensive and unavailable in many countries.<unk>  is sometimes used as a treatment for gynecomastia, although it is probably most effective at this if caught in an early stage (such as in users of anabolic steroids). Some studies have shown that<unk>  can be used to promote spermatogenesis in male patients suffering from nonobstructive azoospermia.<unk>  has also been shown to delay the fusing of the growth plates in mice. When used in combination with growth hormone,<unk>  has been shown effective in one adolescent boy with a short stature.<unk>  has also been used to treat endometriosis. Endometrial stromal sarcomas are hormonally sensitive tumors as it is represented that<unk>  reduces serum estrogen levels.<unk>  is well-tolerated and is a good option for long-term management of this disease. Also in a study on Uterine myoma the volume was successfully reduced by use of an aromatase inhibitor. Rapid onset of action and avoidance of initial gonadotropin flare with an aromatase inhibitor.<unk>  has been documented to be safe and effective for improving height and pubertal outcomes in children living with constitutional delay in growth and puberty, and is better than testosterone with regards to improvement in testicular volume and delaying bone-age progression. This was documented in a meta-analysis published by Dutta et al. which analyzed data from 7 different randomized controlled trials.
Letrozole
Anastrozole
Bisoctrizole
Gestrinone
Norendoxifen
Endoxifen
Tamoxifen
Salvestrol